Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 7, 2018
[ Wed, Mar 07th 2018
] - WOPRAI
[ Wed, Mar 07th 2018
] - WOPRAI
[ Wed, Mar 07th 2018
] - WOPRAI
[ Wed, Mar 07th 2018
] - WOPRAI
[ Wed, Mar 07th 2018
] - WOPRAI
[ Wed, Mar 07th 2018
] - WOPRAI
[ Wed, Mar 07th 2018
] - WOPRAI
[ Wed, Mar 07th 2018
] - WOPRAI
[ Wed, Mar 07th 2018
] - WOPRAI
Tue, March 6, 2018
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
[ Tue, Mar 06th 2018
] - WOPRAI
Matthew Harrison Maintained (SRPT) at Buy with Increased Target to $64 on, Mar 6th, 2018
Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $63 to $64 on, Mar 6th, 2018.
Matthew has made no other calls on SRPT in the last 4 months.
There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Matthew
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $75 on, Wednesday, February 21st, 2018
- Yun Zhong of "Janney Montgomery Scott" Initiated at Strong Buy and Held Target at $75 on, Thursday, January 4th, 2018
- Debjit Chattopadhyay of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $75 on, Friday, December 1st, 2017
